Aspen Pharmacare Holdings Limited (APNHY)
Aspen Pharmacare Holdings Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Durban, NL, ZA. The stock last traded at $9.41, up 0.00% on the session, giving a market capitalisation of $4.18B. On trailing twelve-month figures it carries a trailing P/E of -32.23, a net margin of -5.2%. Its beta of 0.40 implies it has historically moved less than the broad market.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
Aspen Pharmacare Holdings Limited is most often compared with the following Healthcare names: